1. The Official FDA Dual-Threshold Indication Criteria
Anti-obesity medications are not approved as cosmetic treatments. The FDA label for both tirzepatide (Zepbound) and semaglutide (Wegovy) establishes two strict diagnostic gateways:
BMI ≥ 30.0 kg/m²
Individuals with a body mass index of 30 or greater qualify for prescription treatment regardless of whether they have a diagnosed comorbidity. Obesity itself is recognized by the AMA and NIH as a chronic, relapsing metabolic disease.
BMI ≥ 27.0 kg/m² + Comorbidity
Individuals with a BMI between 27.0 and 29.9 qualify if they have at least one weight-related medical complication, including hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or prediabetes.